Hansoh Pharma (03692): Apatinib Mesylate Tablets Approved for Listing by the UK Medicines and Healthcare products Regulatory Agency.

HANSOH PHARMA (03692) announced that its innovative drug Aumseqa (alectinib hydrochloride tablets, known as Aumseqa in the UK) has been approved for sale by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Aumseqa is indicated for use as a monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have activating epidermal growth factor receptor (EGFR) mutations, as well as for the treatment of adult patients with locally advanced or metastatic NSCLC who are positive for the EGFR T790M mutation.